Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone201-804-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$532.09 million
Profitability
Miscellaneous
Employees1,732
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Cambrex (NYSE:CBM) Frequently Asked Questions
What is Cambrex's stock symbol?
Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."
How were Cambrex's earnings last quarter?
Cambrex Co. (NYSE:CBM) issued its earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.05. The biotechnology company had revenue of $152.05 million for the quarter, compared to analyst estimates of $132.78 million. Cambrex had a net margin of 9.41% and a return on equity of 8.20%. The firm's revenue was up 13.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.76 EPS. View Cambrex's Earnings History.
When is Cambrex's next earnings date?
What price target have analysts set for CBM?
5 brokers have issued 1-year price targets for Cambrex's stock. Their forecasts range from $43.00 to $60.00. On average, they expect Cambrex's share price to reach $52.40 in the next twelve months. This suggests that the stock has a possible downside of 12.1%. View Analyst Price Targets for Cambrex.
What is the consensus analysts' recommendation for Cambrex?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cambrex.
Has Cambrex been receiving favorable news coverage?
News stories about CBM stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cambrex earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Cambrex.
Who are some of Cambrex's key competitors?
Some companies that are related to Cambrex include Perrigo (PRGO), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Sarepta Therapeutics (SRPT), Dr.Reddy's Laboratories (RDY), Beigene (BGNE), ACADIA Pharmaceuticals (ACAD), Amarin (AMRN), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), The Medicines (MDCO), Allakos (ALLK) and United Therapeutics (UTHR).
What other stocks do shareholders of Cambrex own?
Who are Cambrex's key executives?
Cambrex's management team includes the folowing people:
- Mr. Steven M. Klosk, Pres, CEO & Director (Age 62)
- Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy and CFO (Age 53)
- Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 53)
- Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 41)
- Mr. James G. Farrell, VP & Corp. Controller (Age 52)
Who are Cambrex's major shareholders?
Cambrex's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.86%), Vanguard Group Inc. (10.41%), William Blair Investment Management LLC (7.84%), Bank of New York Mellon Corp (3.57%), Price T Rowe Associates Inc. MD (1.91%) and Northern Trust Corp (1.90%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.
Which major investors are selling Cambrex stock?
CBM stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Invesco Ltd., Janus Henderson Group PLC, Janus Henderson Group PLC, Renaissance Technologies LLC, Natixis Advisors L.P., Man Group plc and SG Americas Securities LLC. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Shawn Cavanagh and Steven M Klosk. View Insider Buying and Selling for Cambrex.
Which major investors are buying Cambrex stock?
CBM stock was bought by a variety of institutional investors in the last quarter, including Waddell & Reed Financial Inc., Nuveen Asset Management LLC, BlackRock Inc., Ontario Teachers Pension Plan Board, Scout Investments Inc., Public Employees Retirement Association of Colorado, Global Alpha Capital Management Ltd. and Vanguard Group Inc.. View Insider Buying and Selling for Cambrex.
How do I buy shares of Cambrex?
Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cambrex's stock price today?
One share of CBM stock can currently be purchased for approximately $59.61.
How big of a company is Cambrex?
Cambrex has a market capitalization of $2.01 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.View Additional Information About Cambrex.
What is Cambrex's official website?
How can I contact Cambrex?
Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]
MarketBeat Community Rating for Cambrex (NYSE CBM)
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
